SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is trending after exceeding revenue estimates and detailing operational improvements under its "Opendoor 2.0" strategy, with the CEO confirming a path to adjusted EBITDA profitability by Q2. This has ignited robust bullish sentiment for a turnaround, drawing comparisons to Carvana, while skeptics point to ongoing losses and revenue decline.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as the Supreme Court's decision to strike down sweeping tariffs ignites fervent community debate, with many viewing it as a significant blow to former President Trump's economic agenda and a win for consumers, while others speculate it provides a strategic opportunity to reframe economic narratives.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending amid anticipation and delays surrounding a Supreme Court ruling on tariffs, a decision the community believes could significantly impact the company. However, many express frustration over NKE's inability to sustain gains, viewing its price action as a "value trap" despite ongoing strategic resets and efforts to reignite growth.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is a hot topic as it plays a key role in the expanding AI data center market, driven by its new high-powered laser and increasing 800G transceiver orders, leading to raised analyst price targets. Community discussions are highly active, centering on potential for a short squeeze and the stock's pronounced volatility within the optical components sector.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

The Supreme Court's ruling against Trump-era tariffs is driving conversation and a rally in SPY, as many perceive it as disinflationary and supportive of potential rate cuts, though bears remain skeptical, citing other concerning economic data and anticipating a market pullback.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending as the market awaits a Supreme Court decision on tariffs, which could significantly benefit the retail sector. Concurrently, the community is actively discussing ongoing management uncertainty surrounding the search for a new CEO and recent product quality concerns, including the "Get Low" leggings issue, despite upbeat Q4 guidance.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending amidst reports of financing challenges for a major data center project and class-action lawsuits alleging misleading investors regarding capacity and delays. This has sparked a heated debate, with bears highlighting debt and an unsustainable model, while bulls dismiss the negative news as short-seller tactics ahead of anticipated strong earnings, often citing the company's substantial backlog and NVIDIA's investment.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAIL is trending due to a substantial stock decline following mixed results from its NHS-Galleri trial, which missed its primary endpoint for reducing late-stage cancers but showed promising data in early detection, leading to sharp debate between those who see an overreaction and others predicting further declines.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

Invesco QQQ Trust is surging as the Supreme Court's ruling against broad tariffs sparks optimism among investors, who anticipate a potential easing of inflationary pressures and a clearer path to rate cuts, despite some community skepticism regarding broader economic data.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending following a dual financing announcement, including a $100 million public stock offering priced at $5.45 per share and a $100 million royalty funding deal with RTW Investments. While some in the community express concern over significant dilution, others view this as a strategic move that secures crucial runway for commercialization and validates the company's lead asset, CAN-2409, ahead of its BLA submission and ongoing trials.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Given Average Recommendation of "Hold" by Brokerages

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) have earned a consensus rating of "Hold" from the five ratings firms that are presently covering the firm, MarketBeat.com...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Sees Significant Increase in Short Interest

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 30th, there was short interest...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a large increase in short interest during the month of January. As of January 15th, there was short interest...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a significant decrease in short interest during the month of December. As of December 31st, there was short...

OKYO Pharma (NASDAQ:OKYO) Trading Down 15.5% - What's Next?

OKYO Pharma (NASDAQ:OKYO) Shares Down 15.5% - Should You Sell...

OKYO Pharma CEO Gary Jacob Transitions To CDO; Appoints Robert Dempsey As CEO

(RTTNews) - OKYO Pharma Ltd. (OKYO), on Monday, said it has appointed Robert Dempsey as Chief Executive Officer, effective immediately...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totaling...

OKYO Pharma (NASDAQ:OKYO) Stock Rating Upgraded by B. Riley

B. Riley raised OKYO Pharma to a "strong-buy" rating and set a $5.00 target price for the company in a research report on Monday...

OKYO Pharma (NASDAQ:OKYO) Shares Down 4.5% - Time to Sell?

OKYO Pharma (NASDAQ:OKYO) Shares Down 4.5% - Here's Why...

Shares of OKYO Pharma (OKYO) jumped 8% on Monday morning after the company said that it is now planning to advance to a multiple-ascending-dose (MAD) clinical trial for its lead drug candidate Urcosimod.Urcosimod is being developed to treat neuropathic corneal pain (NCP), a condition that causes severe pain and sensitivity of the eyes, face, or head, and is thought to result from nerve damage to the cornea combined with inflammation.In July, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://okyopharma.com/okyo-pharma-announces-registration-pathway-with-100-patient-multi-center-clinical-trial-of-urcosimod-in-neuropathic-corneal-pain/">announced</a> data from a mid-stage trial of Urcosimod in 17 NCP patients. After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% Urcosimod showed greater than 80% reduction in neuropathic corneal pain in that study, as measured by visual analog scale.Okyo said on Monday that it is now focused on advancing to a multiple-ascending-dose (MAD) clinical trial designed to enroll approximately 100 NCP patients across several U.S. clinical sites. The purpose of the trial is to identify the optimal registration dose for Urcosimod for future late-stage trials and to develop an understanding of the drug’s characteristics.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OKYO">OKYO stock</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:578/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_22_at_1_09_35_PM_png_4bfce5981c.webp" alt="OKYO's Sentiment Meter and Message Volume as of 1:09 p.m. ET on Sept. 22, 2025 | Source: Stocktwits" width="578" height="57"><figcaption>OKYO's Sentiment Meter and Message Volume as of 1:09 p.m. ET on Sept. 22, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that they now see a “clear route forward.”<stembedurl>https://stocktwits.com/rp6577/message/629485633</stembedurl>The company said that it expects data from this new trial in 2026, and negotiations are underway with several clinical sites in the U.S. Okyo continues to progress toward a meeting with the U.S. Food and Drug Administration (FDA) to discuss requirements for an approvable drug to treat NCP and to define the primary endpoint required for potential registration, it said.“Our next &nbsp;MAD clinical trial is designed to give us the data needed to define an optimal registration pathway for urcosimod, and we are moving rapidly to initiate this study. With Fast-Track designation in place and a constructive engagement anticipated with FDA, we are well-positioned to bring this novel therapy closer to patients in need,” said CEO Gary S Jacob.OKYO stock is up 85% this year and approximately 112% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lyft-awarded-with-yet-another-price-target-hike-after-waymo-partnership/chDQu3aR32s">Lyft Awarded With Yet Another Price Target Hike After Waymo Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

OKYO Pharma Stock Rises After Company Outlines Development Pathway For Neuropathic Corneal Pain Drug

Okyo announced on Monday that it is now focused on advancing to a multiple-ascending-dose clinical trial, designed to enroll approximately 100 patients with neuropathic corneal pain across several U.S. clinical sites.

Equity

Okyo announced on Monday that it is now focused on advancing to a multiple-ascending-dose clinical trial, designed to enroll approximately 100 patients with neuropathic corneal pain across several U.S. clinical sites.


OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. It operates through the US and UK geographical segments. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.

OKYO
Pharma Limited

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest OKYO News

OKYOPharma Limited